ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978

Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, Non-Hodgkin · Arthritis, Rheumatoid · Sjogren's Syndrome, led by Cullinan Therapeutics.

Drug pageAnti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since May 5, 20234 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cullinan Therapeutics43 open or runningphase 1since May 5, 2023May 5, 2023Dec 2026phase 1 · NCT06613360

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2023First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05879744 · 3 enrolled · United States
  2. Sep 20, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06613360 · 24 planned · United States, Australia, Bulgaria and more
  3. May 20, 2025Phase 1 study in Arthritis, RheumatoidNCT06994143 · 37 planned · Germany, Italy
  4. Jun 18, 2025Phase 1 study in Sjogren's SyndromeNCT07041099 · 36 planned · United States, France, Germany and more

Ahead

  1. Dec 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06613360
  2. Dec 30, 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT06994143
  3. Mar 15, 2028Primary completion: phase 1 study in Sjogren's SyndromeNCT07041099

TargetBeta

CD19 →CD3E →read by rule
“A half-life extended T-cell engaging bispecific antibody comprised of a single chain variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable domain (VHH)-based antibody specific for human se”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07041099Sjogren's Syndrome · United States, France, Germany and more1RecruitingMar 15, 202836
NCT06994143Arthritis, Rheumatoid · Germany, Italy1RecruitingDec 30, 202737
NCT06613360Lupus Erythematosus, Systemic · United States, Australia, Bulgaria and more1RecruitingDec 202624
NCT05879744Lymphoma, Non-Hodgkin · United States1TerminatedJun 1, 20243

How it is read

Names in the registry

  • “CLN-978”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.